These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20934558)

  • 1. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]).
    Carson P; Fiuzat M; O'Connor C; Anand I; Plehn J; Lindenfeld JA; Silver M; White M; Miller A; Davis G; Robertson AD; Bristow M; Gottlieb S
    Am Heart J; 2010 Oct; 160(4):649-54. PubMed ID: 20934558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes.
    O'Connor CM; Fiuzat M; Lindenfeld J; Miller A; Lombardi C; Carson P; Shaw LK; Wang LJ; Connolly P; Mills R; Yancy C; Mahaffey K
    Am J Cardiol; 2011 Nov; 108(10):1449-57. PubMed ID: 21890092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.
    Caro JJ; Migliaccio-Walle K; O'Brien JA; Nova W; Kim J; Hauch O; Hillson E; Wedel H; Hjalmarson A; Gottlieb S; Deedwania PC; Wikstrand J;
    J Card Fail; 2005 Dec; 11(9):647-56. PubMed ID: 16360958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P; Tognoni G; Cohn JN
    J Card Fail; 2003 Jun; 9(3):164-71. PubMed ID: 12815565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure Study.
    Tyl B; Lopez Sendon J; Borer JS; Lopez De Sa E; Lerebours G; Varin C; De Montigny A; Pannaux M; Komajda M
    Circ Heart Fail; 2020 Jul; 13(7):e006720. PubMed ID: 32580655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST).
    Tate CW; Robertson AD; Zolty R; Shakar SF; Lindenfeld J; Wolfel EE; Bristow MR; Lowes BD
    J Card Fail; 2007 Nov; 13(9):732-7. PubMed ID: 17996821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of benefit and early hazard of bucindolol for Class IV heart failure.
    Anderson JL; Krause-Steinrauf H; Goldman S; Clemson BS; Domanski MJ; Hager WD; Murray DR; Mann DL; Massie BM; McNamara DM; Oren R; Rogers WJ;
    J Card Fail; 2003 Aug; 9(4):266-77. PubMed ID: 13680547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blocker use and outcomes among hospitalized heart failure patients.
    Butler J; Young JB; Abraham WT; Bourge RC; Adams KF; Clare R; O'Connor C;
    J Am Coll Cardiol; 2006 Jun; 47(12):2462-9. PubMed ID: 16781374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
    Deedwania PC; Giles TD; Klibaner M; Ghali JK; Herlitz J; Hildebrandt P; Kjekshus J; Spinar J; Vitovec J; Stanbrook H; Wikstrand J;
    Am Heart J; 2005 Jan; 149(1):159-67. PubMed ID: 15660048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).
    Gullestad L; Wikstrand J; Deedwania P; Hjalmarson A; Egstrup K; Elkayam U; Gottlieb S; Rashkow A; Wedel H; Bermann G; Kjekshus J;
    J Am Coll Cardiol; 2005 Jan; 45(2):252-9. PubMed ID: 15653024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
    Bristow MR; Krause-Steinrauf H; Nuzzo R; Liang CS; Lindenfeld J; Lowes BD; Hattler B; Abraham WT; Olson L; Krueger S; Thaneemit-Chen S; Hare JM; Loeb HS; Domanski MJ; Eichhorn EJ; Zelis R; Lavori P
    Circulation; 2004 Sep; 110(11):1437-42. PubMed ID: 15337700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]).
    de Boer RA; Doehner W; van der Horst IC; Anker SD; Babalis D; Roughton M; Coats AJ; Flather MD; van Veldhuisen DJ;
    Am J Cardiol; 2010 Jul; 106(1):78-86.e1. PubMed ID: 20609652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
    Lindenfeld J; Feldman AM; Saxon L; Boehmer J; Carson P; Ghali JK; Anand I; Singh S; Steinberg JS; Jaski B; DeMarco T; Mann D; Yong P; Galle E; Ecklund F; Bristow M
    Circulation; 2007 Jan; 115(2):204-12. PubMed ID: 17190867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blocker treatment of chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study.
    Jost A; Rauch B; Hochadel M; Winkler R; Schneider S; Jacobs M; Kilkowski C; Kilkowski A; Lorenz H; Muth K; Zugck C; Remppis A; Haass M; Senges J;
    Eur Heart J; 2005 Dec; 26(24):2689-97. PubMed ID: 16183697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure.
    Dhaliwal AS; Habib G; Deswal A; Verduzco M; Souchek J; Ramasubbu K; Aguilar D; Ma TS; Jneid HM; Bolos M; Bozkurt B
    Am J Cardiol; 2009 Jul; 104(2):270-5. PubMed ID: 19576359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy.
    O'Connor CM; Gottlieb S; Bourque JM; Krause-Steinrauf H; Anand I; Anderson JL; Plehn JF; Silver MA; White M; Carson P;
    Am J Cardiol; 2005 Mar; 95(5):558-64. PubMed ID: 15721091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.
    Fonarow GC; Abraham WT; Albert NM; Gattis WA; Gheorghiade M; Greenberg B; O'Connor CM; Yancy CW; Young J
    Am Heart J; 2004 Jul; 148(1):43-51. PubMed ID: 15215791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC; Stough WG; Abraham WT; Albert NM; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Am Coll Cardiol; 2007 Aug; 50(8):768-77. PubMed ID: 17707182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.